Harvard University, Cambridge, 2001, BA (Biochemical Sciences)
David Geffen School of Medicine at UCLA, Los Angeles, 2008, MD, PhD
Brigham and Women’s Hospital, Boston, 2010, Residency in Internal Medicine
Dana-Farber/Harvard Cancer Center, 2014, Fellowship in Medical Oncology
The Saha Laboratory studies a highly lethal form of liver cancer called cholangiocarcinoma, or biliary tract cancer, which has been increasing in incidence worldwide for decades. We use a series of unique model systems that we have developed, including genetically engineered mouse models, patient-derived xenografts and cell lines to understand the fundamental pathogenic mechanisms of liver carcinogenesis and to identify new targeted therapies for specific genetic subsets of this disease. Our long-term goal is to transform the standard of care in cholangiocarcinoma from combination chemotherapy for all patients to ‘precision medicine’ with a specific targeted therapy regimen designed for each patient’s molecular profile.
In addition to running a laboratory, Dr. Saha is a medical oncologist with a clinical interest in liver cancer, particularly cholangiocarcinoma and hepatocellular carcinoma.